Akso Health Group Announces Launch of Exploratory Global Patient Support Initiative

Rhea-AI Summary

Akso Health (NASDAQ: AHG) launched an exploratory global patient support initiative and a strategic cooperation with Nanning Duoling Research Institute on Feb 3, 2026. The program aims to coordinate medical resources to provide free in-hospital treatment plans for up to 10,000 eligible patients through an integrated "TCM practice + modern medical technology" model.

The plan connects planned radiation oncology centers, targeted drugs, and remote consultation teams, with Nanning Duoling supplying diagnostic technologies, reagents, lab testing, and expert teams. Participation is limited, phased, conditional on eligibility, institutional qualifications, regulatory requirements, and funding.

Positive

• Up to 10,000 eligible patients targeted for free in-hospital treatment plans
• Strategic cooperation grants access to exclusive diagnostic technologies and supply systems
• Planned global network linking radiation oncology centers, targeted drugs, and remote consultation

Negative

• Program is exploratory and conditional, subject to eligibility, institutional qualifications, regulatory requirements, and funding
• Services will be delivered by independent medical institutions, not the company, limiting direct operational control
• Participation offered on a limited, phased basis, leaving scalability and feasibility unproven

News Market Reaction

-0.68%

3 alerts

-0.68% News Effect

+4.6% Peak Tracked

-$6M Valuation Impact

$883M Market Cap

1.0x Rel. Volume

On the day this news was published, AHG declined 0.68%, reflecting a mild negative market reaction. Argus tracked a peak move of +4.6% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $6M from the company's valuation, bringing the market cap to $883M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Eligible patients: up to 10,000 patients Global new cancer patients: more than 20 million patients New cancer cases in China: 4.06 million cases +5 more

8 metrics

Eligible patients up to 10,000 patients Free in-hospital treatment plans within participating institutions

Global new cancer patients more than 20 million patients Annual global new cancer cases mentioned as target need

New cancer cases in China 4.06 million cases Annual new cancer cases in China referenced by the company

Sales & marketing spend US$168,421 Year ended March 31, 2024

Prior sales & marketing US$6,661 Prior year comparison to FY ended March 31, 2024

G&A expenses US$8.6 million Year ended March 31, 2024

Prior G&A expenses US$15.5 million Prior year to March 31, 2024

Net income (discontinued ops) US$11.84 million Year ended March 31, 2024

Market Reality Check

Price: $1.49 Vol: Volume 3,113 is below the...

low vol

$1.49 Last Close

Volume Volume 3,113 is below the 20-day average of 12,246 (relative volume 0.25x). low

Technical Price $1.47 is trading below the 200-day MA $1.56 and about 30% under the 52-week high.

Peers on Argus

AHG rose about 3.52% while peers showed mixed moves: OMI up 2.19%, HSIC slightly...

AHG rose about 3.52% while peers showed mixed moves: OMI up 2.19%, HSIC slightly down 0.21%, QIPT flat, YI up 16.9%, and INMD up 4.73%, indicating stock-specific rather than broad sector momentum.

Market Pulse Summary

This announcement describes an exploratory global patient support program targeting up to 10,000 eli...

Analysis

This announcement describes an exploratory global patient support program targeting up to 10,000 eligible patients and addressing a pool of more than 20 million new cancer cases worldwide and 4.06 million in China. It emphasizes "zero-cost" access via independent licensed institutions and a strategic cooperation on cancer diagnostics. Investors may watch how participation scales, how regulatory conditions evolve, and how the initiative connects with Akso’s existing oncology-related infrastructure.

Key Terms

traditional chinese medicine (tcm), radiation oncology, reagent, laboratory testing

4 terms

traditional chinese medicine (tcm) medical

"Adopting an integrated model of "Traditional Chinese Medicine (TCM) practice + modern..."

A centuries‑old system of health care that uses herbs, acupuncture, dietary guidance and physical therapies based on the idea of restoring a person’s balance of energy and bodily functions. For investors it matters because products and services labeled as TCM move through regulatory approval, supply chains and consumer markets differently than conventional drugs; changes in safety data, insurance coverage or export rules can quickly affect sales, costs and company value.

radiation oncology medical

"connecting the radiation oncology centers under its planning and construction..."

Radiation oncology is the medical specialty that uses carefully controlled beams of radiation to shrink or destroy tumors, much like using a focused heat lamp or precise scissors to remove a problem area without cutting away healthy tissue. For investors, it matters because demand for radiation oncology drives sales of expensive machines, software, treatment services and related drugs, and is influenced by regulation, reimbursement and technological advances that can change profit potential across equipment makers, hospitals and service providers.

reagent medical

"diagnosis and treatment technologies, reagent and consumable supply system..."

A reagent is a chemical or biological substance used in laboratory tests and manufacturing to cause, detect or measure reactions—think of it as an ingredient in a lab recipe. For investors, reagents matter because their availability, cost, quality and regulatory approval affect a company’s ability to develop diagnostics, produce drugs or run experiments, which in turn influences revenue, margins and operational risk.

laboratory testing medical

"professional laboratory testing capabilities, and an exclusive team composed of experts..."

Laboratory testing is the controlled examination of samples or materials in a lab to measure properties, detect contaminants, verify performance, or prove safety and effectiveness—think of it as a product’s quality-control report card or a recipe trial to ensure the final dish works. For investors, lab tests matter because their results influence regulatory approvals, product launches, safety recalls, development timelines and cost estimates, all of which can affect a company’s revenue and risk profile.

AI-generated analysis. Not financial advice.

QINGDAO, China, Feb. 3, 2026 /PRNewswire/ -- Akso Health Group (NASDAQ: AHG) ("Akso Health" or the "Company") today announced the launch of the an exploratory patient support program and a strategic cooperation with Nanning Duoling Research Institute. Adopting an integrated model of "Traditional Chinese Medicine (TCM) practice + modern medical technology", certain medical resources will be coordinated and integrated to provide free in-hospital treatment plans for up to 10,000 eligible patients within participating medical institutions. The patient support program directly addresses the urgent needs of cancer patients and reconstructs the standards of medical accessibility through "global resource integration + zero-cost access".

Akso Health plans to open its global medical network, connecting the radiation oncology centers under its planning and construction withtargeted drugs andremote consultation teams. Pursuant to a strategic cooperation framework agreement, Nanning Duoling will provide its exclusive cancer diagnosis and treatment technologies, reagent and consumable supply system, professional laboratory testing capabilities, and an exclusive team composed of experts in the field of cancer diagnosis and treatment.  The two parties will work together to build a closed-loop model of "global resource connection + local technology landing + full-cycle patient service", and the core breakthrough of this model is "zero-cost full-chain coverage", which directly addresses the core pain points of high medical costs, difficulty in accessing medical care, and uneven treatment effects faced by more than 20 million new cancer patients worldwide and 4.06 million new annual cases in China.

This program is an important initiative for the Company to continuously explore how to improve the actual accessibility of specific medical support resources within the compliant medical system. It aims to explore a potential framework for coordinating and integrating third-party medical resources through licensed and compliant medical institutions to help patients obtain specific medical services. Any services that may be provided under the program will be fully offered by independent medical institutions and licensed medical professionals, rather than directly by the Company. Specific arrangements, if any, must meet conditions such as patient eligibility, institutional qualifications, applicable regulatory requirements, and funding accessibility.

The Company believes that the launch of this exploratory global patient support initiative may allow for further assessment of scalability and feasibility, subject to ongoing review.

Akso Health emphasized that the long-term value of healthcare innovation lies not only in research and development, but also in the ability to responsibly evaluate implementation models within real-world medical systems. Through the integration of institutional experience, research collaboration, and system-level coordination, the Company continues to explore ways to support sustainable and compliant healthcare accessibility.

Yilin (Linda) Wang, Chief Executive Officer of Akso Health Group, stated,
"We believe it is important to responsibly explore ways to support broader access to healthcare resources, while fully respecting regulatory boundaries and the essential role of licensed medical professionals. This initiative represents an early-stage effort, and we intend to proceed cautiously and deliberately."

The initiative is designed to assess potential approaches to enhancing healthcare accessibility through structured coordination and support mechanisms, while maintaining a clear separation between the Company's corporate activities and the delivery of regulated medical services. Participation, if available, would be offered on a limited and phased basis and does not involve any commercial promotion of medical products or therapies.

Patients or family members interested in participating in the free treatment support program may register or make inquiries via the following email address: ir@ahgtop.com. All applications will be collected centrally, and eligible applicants will be contacted in due course.

About Akso Health Group

Akso Health Group (NASDAQ: AHG), formerly known as Xiaobai Maimai Inc., upon exploration of e-commerce platforms, the Company started exploring the healthcare equipment and product trading and related healthcare services business. Currently, the Company specializes in the sales of medical devices in China and in the United States and also conducts certain radiotherapy oncology center-related operations in the United States. In March 2024, the Company indirectly acquired equity interests in Tianjin Deyihui Internet Hospital and Tianjin Deyihui Clinic Co., Ltd., which provide online medical consultations for initial diagnosis, follow-up consultations, and management of chronic diseases.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "potential," "continue," "ongoing," "targets," "guidance" and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements that involve factors, risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors and risks include, but not limited to the following: risks related to our ability to obtain equipment, technology, license and talents at satisfactory terms to grow the medical equipment business and/or to start the planned healthcare business, if at all; risks related to the Company's ability to adapt and make the necessary adjustments to compete and operate effectively; risks related to decisions or changes in governmental policies in the healthcare segment; risks related to increased competition and the development of new competing services; the risk that we may be unable to develop or achieve commercial success for our medical and healthcare services in a timely manner, or at all; risks related to regulatory requirements or enforcement in relevant jurisdiction and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to successfully integrate and derive benefits from any technologies that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; and risks related to uncertainties in regulatory oversight of healthcare-related services, limitations on the promotion or commercialization of unapproved medical products; risks that any evaluated service models may not progress beyond exploratory stages; risks on healthcare service arrangements, limitations on the promotion or delivery of medical-related services, uncertainties regarding third-party medical providers, and the risk that contemplated collaborations may not progress beyond preliminary or framework stages. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the SEC. All information provided in this announcement is current as of the date of this announcement, and the Company does not undertake any obligation to update such information, except as required under applicable law.

For more information, please visit http://www.ahgtop.com/en/index.html 

For investor inquiries, please contact:

Akso Health Group
Investor Relations
Email: ir@ahgtop.com 
Website: www.ahgtop.com

View original content:https://www.prnewswire.com/news-releases/akso-health-group-announces-launch-of-exploratory-global-patient-support-initiative-302677478.html

SOURCE Akso Health Group

FAQ

What exactly did Akso Health (AHG) announce on February 3, 2026 about patient support?

Akso Health announced an exploratory global patient support initiative and a strategic cooperation with Nanning Duoling. According to Akso Health, the program aims to provide free in-hospital treatment plans for up to 10,000 eligible patients through coordinated resources and an integrated TCM-plus-modern-technology model.

How many patients could benefit from the AHG patient support program and what is the scope?

The program targets up to 10,000 eligible patients for free in-hospital treatment plans. According to Akso Health, the initiative connects planned radiation centers, targeted drugs, and remote consultation teams across participating institutions to broaden access.

What role does Nanning Duoling play in Akso Health's AHG program?

Nanning Duoling will provide exclusive cancer diagnosis technologies, reagent and consumable supply, lab testing, and expert teams. According to Akso Health, this cooperation supports a closed-loop model for local technology landing and full-cycle patient service.

Will Akso Health directly provide medical treatment under the AHG initiative?

No. Akso Health stated services will be fully provided by independent licensed medical institutions and professionals. According to Akso Health, the company will coordinate resources but will not directly deliver regulated medical services.

What limitations or conditions affect participation in the AHG free treatment program?

Participation is limited and phased, subject to patient eligibility, institutional qualifications, regulatory requirements, and funding access. According to Akso Health, these conditions mean scalability and feasibility will be assessed over time before wider rollout.